NCCN 3rd Annual Congress on Hematologic Malignancies

 
 
 

The NCCN 3rd Annual Congress on Hematologic Malignancies took place September 5-6, 2008, in Brooklyn, New York.

 

Early transplantation is more cost effective for multiple myeloma patients

Mark Fuerst Read Article
Published: 09/16/08

Seema Singhal, MD
Seema Singhal, MD

The decision of when to initiate transplant in a multiple myeloma patient may be easier if physicians consider the cost of treatment. Early transplant is more financially beneficial than late transplant for patients with multiple myeloma, according to Seema Singhal, MD, of Northwestern University in Chicago. At the NCCN 3rd Annual Congress on Hematologic Malignancies, Dr Singhal presented 2 scenarios that demonstrated the eventual costs of early versus late transplantation. [Read Article]

Radioimmunotherapy underused in lymphoma

Jen Smith Read Article
Published: 09/12/08

Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD

Despite demonstrating a clear clinical benefit, radioimmunotherapy (RIT) is underused in lymphoma patients, according to a speaker at the NCCN 3rd Annual Congress on Hematologic Malignancies. Andrew D. Zelenetz, MD, PhD, referenced studies showing that RIT elicits high response rates, improves patient survival, and results in only moderate toxicities. So, he went on to ask, why do clinicians shy away from administering this therapy? [Read Article]

NCCN panel members discuss effects of new ESA guidelines

Mark Fuerst Read Article
Published: 09/12/08

Drs Charles Bennett, Eric Kraut, and Pamela Becker
Drs Charles Bennett, Eric Kraut,
and Pamela Becker

The updated package insert for erythropoiesis-stimulating agents (ESAs), mailed by drug manufacturers in early August, strikes out phrases and pares down the drugs' indications. The NCCN has updated its treatment guidelines to comply with the revised package insert. But three members of the panel that approved the NCCN update are concerned about the effects of these changes. They voiced their concerns at the NCCN 3rd Annual Congress on Hematologic Malignancies. [Read Article]

Myeloma patients retain negative outlook despite therapeutic advances

Jen Smith Read Article
Published: 09/11/08

Kenneth C. Anderson, MD
Kenneth C. Anderson, MD

The recent clinical success of novel therapies for multiple myeloma is dampened by complications resulting from these therapies and the disease itself, according to a speaker at the NCCN 3rd Annual Congress on Hematologic Malignancies. Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, said, despite improvements in treatment response and survival, multiple myeloma patients retain a negative outlook on their disease because of adverse events. [Read Article]

Novel therapeutic method proves effective in adult ALL

Jen Smith Read Article
Published: 09/10/08

New data may encourage clinicians to modify their approach to treating adult ALL patients. A study presented at the NCCN 3rd Annual Congress on Hematologic Malignancies suggests intensified pediatric protocols can improve response and survival rates in adult ALL patients. Leonardo Andres Sirulnik, MD, PhD, of Dana-Farber Cancer Institute, presented a study of 95 adults with ALL treated according to the Dana-Farber Cancer Institute pediatric regimen. [Read Article]

Expert recommends cautious approach to treating CTCL

Jen Smith Read Article
Published: 09/09/08

Steven M. Horwitz, MD
Steven M. Horwitz, MD

A cautious approach is often best when treating cutaneous T-cell lymphoma, according to a presenter at the NCCN 3rd Annual Congress on Hematologic Malignancies. Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, said clinicians should begin treating patients with mild therapy, as a general rule. This not only spares them severe toxicities, but patients treated conservatively often have comparable outcomes to those treated aggressively. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}